OxStem
Innovative stem cell therapies targeting disease-specific pathways for regenerative medicine.
| GBP | 2015 | 2016 | 2017 | 2018 | 2019 | 2021 |
|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | - | - | - | - | (1156 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | - | - | - | - | (1087 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
OxStem Limited is a biotechnology company specializing in the development of stem cell therapies aimed at treating a variety of diseases. The company operates in the regenerative medicine market, focusing on creating innovative solutions that target disease-specific pathways. OxStem's business model revolves around extensive research and development (R&D) to discover and develop new therapeutic approaches. The company primarily serves the pharmaceutical and healthcare sectors, collaborating with academic institutions and other biotech firms to advance its research. Revenue is generated through partnerships, licensing agreements, and potentially through the commercialization of its proprietary therapies. OxStem's leadership team includes experienced professionals from the pharmaceutical industry, ensuring strong strategic direction and scientific expertise.
Keywords: stem cell therapies, regenerative medicine, disease-specific pathways, biotechnology, pharmaceutical, healthcare, R&D, partnerships, licensing, commercialization.